$377.4M Equity Offering Finalized by Apogee Therapeutics, Underwriters Exercise Full Option
APGE has more than doubled off its 52-week low of $26.2 on elevated volume (3.3× avg).
Summary
Apogee Therapeutics has finalized its public offering, raising approximately $377.4 million in net proceeds. This updated figure includes the full exercise of the underwriters' option to purchase an additional 750,000 shares, bringing the total offering to 5.75 million shares priced at $70 each. This follows the company's initial announcement of a proposed $300 million offering on March 23rd, which was subsequently priced at $350 million for 5 million shares earlier on March 25th. The capital infusion is significant, representing a material increase to the company's cash reserves, and comes shortly after Apogee reported highly positive 52-week maintenance data from its Phase 2 APEX clinical trial for zumilokibart. While the offering is dilutive and priced below the current market, the substantial capital provides a longer runway to fund ongoing clinical development and advance its pipeline.
At the time of this announcement, APGE was trading at $78.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $26.20 to $85.04. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.